



Principal Scientist / Senior Scientist, Cancer Immunotherapy
Job Code 401EP

Description

Fate Therapeutics is seeking a highly motivated Immunologist with expertise in immune oncology to join a multidisciplinary team dedicated to the discovery of novel cellular therapeutics. The candidate must have in-depth knowledge of NK or T cell biology, with a focus on cell-based therapy and solid tumors. Extensive experience with *in vitro* functional characterization of NK or T cells is required. Experience with *in vivo* cell-derived xenograft, patient-derived xenograft, and/or syngeneic tumor models is highly desired. As a leader in our cancer immunotherapy team, the successful candidate will provide scientific and technical input for ongoing project initiatives in addition to executing and overseeing key *in vitro* and *in vivo* studies. Previous industry experience preferred. This is a full-time position reporting to an Associate Director, Cancer Immunotherapy and is located at the Company's corporate headquarters in San Diego, California.

Responsibilities:

- Execute experiments to test novel iPSC-derived CAR-T cells designed to overcome the tumor microenvironment
- Perform phenotypic and functional analysis of CAR-T cells using multi-parameter flow cytometry and standard *in vitro* assays looking at proliferation, cytokine secretion, polyfunctionality, and target cell killing
- Develop and optimize new *in vitro* assays for testing CAR-T function
- Coordinate and oversee *in vivo* studies and *ex vivo* analysis of iPSC-derived CAR-T cells
- Ensure consistent progress toward achieving team objectives and timelines
- Mentor and manage research associates
- Explore new areas of research in cell-based immunotherapy for solid tumors
- Prepare data packages and present to immunology groups and larger program-specific teams or external collaborators

Qualifications

- Ph.D. degree in Immunology, cancer biology, or other related fields with relevant post-doctoral experience and minimum of 5 years of industry experience
- Strong ability to design, develop and implement novel *in vivo* xenograft and/or syngeneic tumor models
- Excellent working knowledge of standard immunology assays used to characterize T cells or NK cells
- Expertise in multi-color flow cytometry, including intracellular staining
- Experience with transfection, or lentiviral transduction of primary immune cells
- Experience with xCelligence or IncuCyte platforms is desirable
- Experience with spheroid assays is a plus
- Proven ability to coordinate with multiple researchers for scheduling and execution of complex experiments
- Prior experience managing scientists or research associates is a plus
- Excellent communication and organization skills are a must



- Positive outlook, willingness to learn, and a team-oriented attitude

Working Conditions and Physical Requirements

- Will require working with cells and cell lines of human and/or animal origin
- Occasional weekend and/or evening hours required
- 100% on site work at corporate headquarters in San Diego, CA

The preceding job description indicates the general nature and level of work performed by employees within this classification. Additional and incidental duties related to the primary duties may be required from time to time.

For consideration send cover letter and curriculum vitae to: careers@fatetherapeutics.com and reference job 401EP.

About Fate Therapeutics, Inc.

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company's immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company's immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.